Clinical Trials Logo

Rectal Neoplasm Malignant clinical trials

View clinical trials related to Rectal Neoplasm Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT04926324 Recruiting - Rectal Neoplasms Clinical Trials

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Start date: July 7, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.

NCT ID: NCT03587480 Recruiting - Clinical trials for Rectal Neoplasm Malignant

Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy

TELEPHOME
Start date: December 17, 2018
Phase: N/A
Study type: Interventional

Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO). While Japanese scholars advocate total mesorectal excision (TME) plus lateral lymph node dissection (LLND), European and American scholars advocate TME alone after Neoadjuvant Chemo-radiotherapy (nCRT), without the need of LLND. Accordingly, this clinical trial is designed to directly compare the efficacy and safety of these two treatment strategies for low rectal cancer with regional lymph node metastasis. It will provide high-level clinical evidence for the treatment of low rectal cancer with suspected local lymph node metastasis

NCT ID: NCT03428529 Completed - Clinical trials for Rectal Neoplasm Malignant

Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.

INCAGI004
Start date: January 12, 2011
Phase: Phase 2/Phase 3
Study type: Interventional

A randomized two-arm study comparing preoperative CRT using oral capecitabine versus bolus 5-FU/LV concomitant to external beam radiation (50.5 Gy/28 fractions) for locally advanced rectal cancer. Main outcome was clinical response assessed using MRI and endorectal US 6-8 weeks after CRT. Secondary endpoints were pathological response, adverse effects, sphyncter preservation, quality of life, OS and DFS.